ESC 365 - Impact of real-world off-label dose of Apixaban on long-term clinical outcomes in patients with atrial fibrillation and chronic kidney disease

ESC Professional Premium Access

Impact of real-world off-label dose of Apixaban on long-term clinical outcomes in patients with atrial fibrillation and chronic kidney disease

Session: Clinical decision-making about oral anticoagulant therapy in atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Doctor H. Shin (Busan, KR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Ho Sik Shin

Kosin University School of Medicine, Busan (Korea (Republic of))

0 follower

8 more presentations in this session

Switching from warfarin to a DOAC in frail elderly asian patients with atrial fibrillation: a nationwide population-based study

Speaker: Doctor Y. Go (Seoul, KR)

Drug interactions in incident NOACs users and risk of bleeding

Speaker: Doctor M. Amadori (Bologna, IT)

Resumption of anticoagulation therapy among Non-Valvular Atrial Fibrillation (NVAF) patients with prior intracranial haemorrhage

Speaker: Doctor W. Sun (Shatin, HK)

Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation

Speaker: Doctor Y. Gue (Liverpool, GB)

The incidence of death and risk factors for mortality following major bleeding in patients anticoagulated with factor Xa inhibitors: an observational study in the UK clinical setting (AXIOM UK)

Speaker: Doctor A. Cohen (London, GB)

Access the full session

Clinical decision-making about oral anticoagulant therapy in atrial fibrillation

Speakers: Doctor H. Shin, Doctor Y. Go, Doctor M. Amadori, Doctor W. Sun, Doctor Y. Gue...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources